Sietse J. Luk

Sietse J. Luk

Auto-generated profile, based on publicly available information

Sietse J. Luk

Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 September 2018 in OncoImmunology
Verified
Journal Article
Open access
SLSietse J Luk
Sietse J Luk
DSDirk M van der Steen
Dirk M van der Steen
RHRenate S Hagedoorn
Renate S Hagedoorn
EJEkaterina S Jordanova
Ekaterina S Jordanova
MSMarco W Schilham
Marco W Schilham
MHMirjam Hm Heemskerk
Mirjam Hm Heemskerk
Synovial sarcoma expresses multiple cancer testis antigens that could potentially be targeted by T-cell receptor (TCR) gene therapy. In this study we investigated whether PRAME-TCR-gene therapy could be an effective treatment for synovial sarcoma by investigating the potential of PRAME-specific T-cells to recognize sarcoma cells and by evaluating the expression patterns of PRAME and HLA class I (HLA-I) in synovial sarcoma tumor samples. All PRAME expressing sarcoma cell lines, including 2 primary synovial sarcoma cell cultures (passage < 3), were efficiently recognized by PRAME-specific T-cells. mRNA FISH demonstrated that PRAME was expressed in all synovial sarcoma samples, mostly in an homogeneous pattern. Immunohistochemistry demonstrated low HLA-I baseline expression in synovial sarcoma, but its expression was elevated in specific areas of the tumors, especially in biphasic components of biphasic synovial sarcoma. In 5/11 biphasic synovial sarcoma patients and in 1/17 monophasic synovial sarcoma patients, elevated HLA-I on tumor cells was correlated with infiltration of T-cells in these specific areas. In conclusion, low-baseline expression of HLA-I in synovial sarcoma is elevated in biphasic areas and in areas with densely infiltrating T-cells, which, in combination with homogeneous and high PRAME expression, makes synovial sarcoma potentially a suitable candidate for PRAME-specific TCR-gene therapy.

11 September 2023 in Cancer Immunology Research
Verified
Journal Article
Open access
PDF file
SLSietse J. Luk
Sietse J. Luk
RSRouven Schoppmeyer
Rouven Schoppmeyer
MIMarieke Erica Ijsselsteijn
Marieke Erica Ijsselsteijn
ASAntonios Somarakis
Antonios Somarakis
IAIbtissam Acem
Ibtissam Acem
MHMirjam H.M. Heemskerk
Mirjam H.M. Heemskerk
Cancers evade T-cell immunity by several mechanisms such as secretion of anti-inflammatory cytokines, down regulation of antigen presentation machinery, upregulation of immune checkpoint molecules, and exclusion of T cells from tumor tissues. The distribution and function of immune checkpoint molecules on tumor cells and tumor-infiltrating leukocytes is well established, but less is known about their impact on intratumoral endothelial cells. Here, we demonstrated that V-domain Ig suppressor of T-cell activation (VISTA), a PD-L1 homolog, was highly expressed on endothelial cells in synovial sarcoma, subsets of different carcinomas, and immune-privileged tissues. We created an ex vivo model of the human vasculature and demonstrated that expression of VISTA on endothelial cells selectively prevented T-cell transmigration over endothelial layers under physiologic flow conditions, whereas it does not affect migration of other immune cell types. Furthermore, endothelial VISTA correlated with reduced infiltration of T cells and poor prognosis in metastatic synovial sarcoma. In endothelial cells, we detected VISTA on the plasma membrane and in recycling endosomes, and its expression was upregulated by cancer cell–secreted factors in a VEGF-A–dependent manner. Our study reveals that endothelial VISTA is upregulated by cancer-secreted factors and that it regulates T-cell accessibility to cancer and healthy tissues. This newly identified mechanism should be considered when using immunotherapeutic approaches aimed at unleashing T cell–mediated cancer immunity.

13 December 2023 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
RWRuud H. Wijdeven
Ruud H. Wijdeven
SLSietse J. Luk
Sietse J. Luk
TSTom A. W. Schoufour
Tom A. W. Schoufour
SZSabina Y. van der Zanden
Sabina Y. van der Zanden
MCMarta Cabezuelo
Marta Cabezuelo
JNJacques Neefjes
Jacques Neefjes
MHC class I (MHC-I) molecules are critical for CD8+ T cell responses to viral infections and malignant cells, and tumors can downregulate MHC-I expression to promote immune evasion. In this study, using a genome-wide CRISPR screen on a human melanoma cell line, we identified the polycomb repressive complex 1 (PRC1) subunit PCGF1 and the deubiquitinating enzyme BAP1 as opposite regulators of MHC-I transcription. PCGF1 facilitates deposition of ubiquitin at H2AK119 at the MHC-I promoters to silence MHC-I, whereas BAP1 removes this modification to restore MHC-I expression. PCGF1 is widely expressed in tumors and its depletion increased MHC-I expression in multiple tumor lines, including MHC-Ilow tumors. In cells characterized by poor MHC-I expression, PRC1 and PRC2 act in parallel to impinge low transcription. However, PCGF1 depletion was sufficient to increase MHC-I expression and restore T cell–mediated killing of the tumor cells. Taken together, our data provide an additional layer of regulation of MHC-I expression in tumors: epigenetic silencing by PRC1 subunit PCGF1.

21 August 2025 in Blood
Verified
Journal Article
Closed access
EPEmma S. Pool
Emma S. Pool
SLSietse J. Luk
Sietse J. Luk
MIMarieke Erica Ijsselsteijn
Marieke Erica Ijsselsteijn
VUVincent van Unen
Vincent van Unen
Noel de MirandaNoel de Miranda
Noel de Miranda
JTJennifer Tjon
Jennifer Tjon
The autoimmune response driving hematopoietic stem and progenitor cell (HSPC) destruction in immune-mediated aplastic anemia (AA) remains incompletely understood. We previously identified a disease-specific immune cell network involving T, B, and myeloid cells. However, the interactions within this network, the interaction with the microenvironment, and the chronological events in AA development, remain unclear. In this study, we aimed to characterize the changes occurring during disease development and to define the interactions between potential autoreactive cells and their target. Using imaging mass cytometry, we analyzed bone marrow (BM) biopsies from patients with AA at diagnosis and after treatment with horse-derived anti–thymocyte globulin (hATG), and 6 controls. Within the hypocellular BM architecture, we identified lymphoid-dominant “immune hot spots” with high densities of proinflammatory lymphocytes, and macrophage-enriched hot spots that additionally contained activated macrophages in proximity to progenitors. These immune hot spots potentially represent sites in which the active immune response resulting in HSPC destruction takes place. In BM regions depleted of progenitors, effector cells with a differentiated phenotype remain. Our data indicate that HSPC destruction in AA is mediated by coordinated interactions among specific immune cell subpopulations. As the immune response progresses and HSPCs are depleted, the immune composition shifts, with activated T and B cells differentiating into terminally differentiated T cells and plasma cells. In patients with normalizing BM after hATG treatment, most immune hot spots were depleted, underscoring their potential pathogenic role. Collectively, our study visualizes the complex interactions among immune cell subpopulations and reveals, to our knowledge, for the first time, the order of events in the immune-mediated pathogenesis of AA.

21 December 2024 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Open access
PDF file
SLS. J. Luk
S. J. Luk
MIM. E. Ijsselsteijn
M. E. Ijsselsteijn
ASA. Somarakis
A. Somarakis
IAI. Acem
I. Acem
IBI. Briaire de Bruijn
I. Briaire de Bruijn
MHM. H. M. Heemskerk
M. H. M. Heemskerk
Synovial sarcoma is an aggressive soft-tissue cancer that shows limited responses to current immunotherapeutic approaches using immune checkpoint blockade or adoptive cell therapy. To improve immunotherapy for this cancer, understanding how the immune cells in the tumor microenvironment associate with histological subtype, disease progression and current therapies is vital. To evaluate the immune infiltrate in synovial sarcoma in relation to histological subtype, disease progression and in response to cytotoxic treatment, we performed immunodetection of T cells, CD68+ myeloid cells, endothelial cells and keratin on a series of 41 synovial sarcoma patients at various stages of disease. The immune composition of synovial sarcoma was dominated by CD68+ myeloid cells of which a substantial part was of the CD163+ immunosuppressive phenotype, which increased after chemotherapy or radiotherapy. Biphasic synovial sarcomas were more densely infiltrated by both T cells and myeloid cells than monophasic synovial sarcomas. In these tumors, the immune and endothelial cells were mostly located within the stromal like, spindle cell compartment and excluded from the epithelial compartment, greatly resembling the spatial organization of healthy epithelium such as in the colon. Together these data demonstrate that biphasic synovial sarcoma is immunologically different from monophasic synovial sarcoma and might be more susceptible to immunotherapies such as adoptive T-cell therapy. Finally, T-cell infiltration in primary synovial sarcoma was associated with prolonged overall survival of patients which suggests that intratumoral T cells may demonstrate anti-tumor activity.

11 December 2025
Verified
Other
Open access
SLSietse J. Luk
Sietse J. Luk
RSRouven Schoppmeyer
Rouven Schoppmeyer
MIMarieke Erica Ijsselsteijn
Marieke Erica Ijsselsteijn
ASAntonios Somarakis
Antonios Somarakis
IAIbtissam Acem
Ibtissam Acem
MHMirjam H.M. Heemskerk
Mirjam H.M. Heemskerk
Supplementary Figures and Tables